Most patients initiated full-dose ibrutinib, while reduced starting doses clustered in older, more comorbid, poorer ECOG ...
Combination of Osimertinib and Vascular Endothelial Growth Factor Receptor Inhibitors for EGFR-Mutated Non–Small Cell Lung Cancer: Old or New Regimen? In the article that accompanies this editorial, ...
Bottom Line: Adding the investigational antibody ianalumab (VAY736) to ibrutinib (Imbruvica) allowed some patients with chronic lymphocytic leukemia (CLL) to discontinue daily therapy and potentially ...
Learn how age, TP53 risk, and lifestyle shape choosing fixed-duration vs continuous CLL therapy, with shared decision tips from Dr Lamanna. While results from the CLL17 trial (NCT04608318) suggest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results